Table 2.

Mutant KRAS targeted drugs for pancreatic cancer treatment

Drugs	Mechanism	Efficacy
FTIs (Lonafarnib and Tipifarnib)	Inhibiting farnesylation of KRAS	Not promising
FTS, salirasib	Preventing KRAS from reaching cell membranes	Promising
Deltarasin	Enabling KRAS to be farnesylated but halting it from reaching the membrane	Decreasing the proliferation of KRAS-driven PDAC cell lines
CI-1040 and PD0325901	Inhibiting MEK/MAPK pathway downstream of KRAS	Not significant
LY294002	Inhibiting PI3K pathway downstream of KRAS	Promoting apoptosis in vitro and preventing tumor proliferation in vivo